RenovoRx, Inc.
RNXT
$1.34
-$0.01-0.74%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 358.14% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 358.14% | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 139.53% | -- | |||
| SG&A Expenses | 42.95% | -6.71% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 23.63% | -5.41% | |||
| Operating Income | -18.16% | 6.93% | |||
| Income Before Tax | 15.91% | -16.47% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 15.91% | -16.47% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 15.91% | -16.47% | |||
| EBIT | -18.16% | 6.93% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 32.72% | -15.64% | |||
| Normalized Basic EPS | 32.68% | -15.67% | |||
| EPS Diluted | 32.72% | -15.64% | |||
| Normalized Diluted EPS | 32.68% | -15.67% | |||
| Average Basic Shares Outstanding | 25.05% | 0.67% | |||
| Average Diluted Shares Outstanding | 25.05% | 0.67% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||